Prohibits the sale, offer for sale, or delivery of xylazine

Looking ahead

No hearings or votes scheduled.

History

1. 2026
   1. Mar 10REFERRED TO CONSUMER PROTECTIONLatest
      • Vote recorded Assembly Vote - Vote 3. Result: pass.Lower
   2. Mar 10DELIVERED TO SENATE
   3. Mar 10PASSED ASSEMBLYMajor
   4. Jan 12AMENDED ON THIRD READING (T) 1248CMajor
   5. Jan 7ORDERED TO THIRD READING CAL.44
   6. Jan 7RETURNED TO ASSEMBLY
   7. Jan 7DIED IN SENATE
2. 2025
   1. May 27RECOMMITTED TO CONSUMER PROTECTIONMinor
      • Vote recorded Assembly Vote - Vote 2. Result: pass.Lower
   2. May 27RETURNED TO SENATE
   3. May 27REPASSED ASSEMBLYPassed 2nd Chamber
   4. May 22AMENDED ON THIRD READING 1248BMajor
      • Vote recorded MOTION:TAPIA; To reconsider. Result: pass.Lower
   5. May 22VOTE RECONSIDERED - RESTORED TO THIRD READING
   6. May 22RETURNED TO ASSEMBLY
   7. May 22RECALLED FROM SENATE
   8. May 21REFERRED TO COMMERCE, ECONOMIC DEVELOPMENT AND SMALL BUSINESSMinor
      • Vote recorded Assembly Vote. Result: pass.Lower
   9. May 21DELIVERED TO SENATE
   10. May 21PASSED ASSEMBLYPassed 1st Chamber
   11. May 21ORDERED TO THIRD READING RULES CAL.202
   12. May 21RULES REPORT CAL.202
   13. May 21REPORTED
   14. May 20REPORTED REFERRED TO RULESMinor
   15. Apr 21PRINT NUMBER 1248AMajor
   16. Apr 21AMEND (T) AND RECOMMIT TO WAYS AND MEANSMajor
   17. Apr 2REPORTED REFERRED TO WAYS AND MEANSMinor
   18. Mar 25REPORTED REFERRED TO CODESMinor
   19. Jan 9REFERRED TO CONSUMER AFFAIRS AND PROTECTIONIntroduced